However, accompanied by a promising survival advantage, PD-1/PD-L1 inhibitors are related to a broad spectrum of toxic effects known as immune-related adverse events (irAEs), including skin rash, colitis, hepatitis, endocrinopathies, and pneumonitis (7). Here, PDCD1 is linked to pneumonitis.